Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

Completed

Phase N/A Results N/A

Trial Description

The present study will be conducted to assess the following research questions in real-life conditions in France:
What are the patient and disease characteristics, comorbidities and treatment history in NVAF patients initiating a new Anticoagulant (AC) treatment, according to treatment currently available and prescribed (apixaban, other NOACs, VKAs), and are the AC-naive patient profiles different from one treatment pattern to another when initiating a new AC treatment?
What are the HCP's reasons for discontinuing the previous AC strategy for initiating and choosing the newly initiated AC treatment in NVAF patients?
What are the conditions of newly-initiated apixaban prescriptions in NVAF patients: prescriber, proportion of naïve/experienced patients, daily dosage and number of daily doses?

Conditions

Interventions

Trial Design

  • Observation: Cohort
  • Perspective: Cross-Sectional
  • Sampling: Probability Sample

Trial Population

Cardiologists in france caring AF patients

Outcomes

Type Measure Time Frame Safety Issue
Primary Patient characteristics in NVAF patients initiating a new AC-treatment Approximately 12 months No
Primary Comparing patient characteristics between apixaban and other Novel anticoagulants (NOACs) in AC-naive patients Approximately 12 months No
Primary Comparing patient characteristics between apixaban and Vitamin K antagonists (VKAs) in AC-naive patients Approximately 12 months No
Primary Disease characteristics in NVAF patients initiating a new AC-treatment Approximately 12 months No
Primary Comparing disease characteristics between apixaban and other NOACs in AC-naive patients Approximately 12 months No
Primary Comparing disease characteristics between apixaban and VKAs in AC-naive patients Approximately 12 months No
Primary Comorbidities in NVAF patients initiating a new AC-treatment Approximately 12 months No
Primary Comparing comorbidities characteristics between apixaban and other NOACs in AC-naive patients Approximately 12 months No
Primary Comparing comorbidities characteristics between apixaban and VKAs in AC-naive patients Approximately 12 months No
Primary Treatment history in NVAF patients initiating a new AC-treatment Approximately 12 months No
Primary Comparing treatment history characteristics between apixaban and other NOACs in AC-naive patients Approximately 12 months No
Primary Comparing treatment history characteristics between apixaban and VKAs in AC-naive patients Approximately 12 months No
Secondary Distribution of previous AC strategy (no treatment, apixaban, other NOAC, VKAs) Approximately 12 months No
Secondary Distribution of reasons for discontinuing previous AC treatment among patients who had previous AC treatment Approximately 12 months No
Secondary Distribution of prescriber (Cardiologist him/herself, General Practitioner (GP), other) Approximately 12 months No
Secondary Distribution of reasons for initiating a new AC treatment Approximately 12 months No
Secondary Distribution of reasons for choosing the newly initiated AC treatment Approximately 12 months No
Secondary Conditions of prescription of apixaban in NVAF patients Approximately 12 months No
Secondary Proportion of AC-naive patients Approximately 12 months No
Secondary Proportion of AC-experienced patients Approximately 12 months No
Secondary Mean daily dosage of daily doses for prescribed apixaban treatment according to patient characteristics Approximately 12 months No
Secondary Mean number of daily doses for prescribed apixaban treatment according to patient characteristics Approximately 12 months No

Sponsors